Alexandra Gerlach, Senior Content Producer

BeeR is a bacterial protein from the family Verrucomicrobiota that influences cell shape and division.

As demand for GLP-1 therapies grows, patients face rising costs and restrictive insurance policies.

The combination was approved for treatment of patients with gastroesophageal junction (GEJ) adenocarcinoma.

Exidavnemab is a novel monoclonal antibody with disease-modifying potential.

Reducing the dose of ibrutinib following adverse events improved tolerability without compromising clinical efficacy in chronic lymphocytic leukemia (CLL).

The findings extend prior data underscoring the clinical benefit of the agent and its place in global clinical practice guidelines.

A phase 2 study showed that elotuzumab combined with pomalidomide, bortezomib, and dexamethasone was safe and efficacious.

The patient is the first to be cured using lovotibeglogene autotemcel, a novel cell-based gene therapy.

Tarlatamab was approved by the FDA in May 2024 for patients who progressed after platinum-based chemotherapy.

This marks steps toward improving health care pricing transparency, but further reforms are needed to reduce costs long-term.

Lipid metabolism plays a critical role in the function of T-cells.

The Western diet was associated with increased risk of lung cancer.

Approximately 10% of patients with multiple myeloma have pathogenic germline variants, indicating a hereditary risk.

Use of dexamethasone over tocilizumab was associated with significant cost-savings for patients with relapsed/refractory multiple myeloma (RRMM).

Vepdegestrant is an experimental oral PROteolysis TArgeting Chimera that degrades estrogen receptor (ER) in patients with metastatic breast cancer.

The favorable outcomes were observed in the phase 3 AMPLIFY trial.

The outbreak has grown to a total of 222 confirmed cases of measles, as well as 2 measles-associated deaths.

A pilot program integrated oncology pharmacists into prior authorization workflows to streamline and expedite medication approvals.

Subcutaneous infusion reduces treatment times for patients and eases operational burdens for providers.

Policymakers and health care providers call for reforms to improve transparency, pricing, and patient access.

Specialty pharmacists are critical for enhanced management of clinical and logistical aspects of treatment.

Camizestrant is an investigational oral selective estrogen receptor degrader.

The authors’ findings show a greater decline in those treated with chemotherapy vs endocrine therapy.

The data supports quadruplet therapy’s potential in the first line for patients with newly diagnosed multiple myeloma (NDMM).

The decision is based on clinically meaningful results from a phase 3 trial.

The decisions were made amid the United States worst flu outbreak in over 2 decades.

The data were released in the CDC’s Morbidity and Mortality Weekly Report.

Trastuzumab rezetecan is a novel antibody-drug conjugate.

The advanced therapy yielded superior enhanced mucus secretion compared with available therapies.

Patients achieved an overall survival of 12.4 months.